GeneCentric Therapeutics

Executive Summary

GeneCentric Therapeutics is a precision oncology diagnostics company developing liquid biopsy platforms that uniquely integrate high-fidelity DNA alteration detection with comprehensive gene expression profiling. This dual approach aims to provide a more complete view of tumor biology from a simple blood draw, addressing critical unmet needs in cancer biomarker development. The company's technology has the potential to improve early detection, treatment selection, and disease monitoring across multiple cancer types, positioning it as a distinct player in the rapidly evolving liquid biopsy market. The company is privately held and based in Durham, North Carolina. While still in a relatively early stage, GeneCentric has demonstrated the ability to combine two traditionally separate analytical modalities—genomic alterations and transcriptomic signatures—into a single, scalable assay. This differentiator could enable more accurate molecular profiling, especially in scenarios where tissue biopsies are challenging or insufficient. As the demand for non-invasive, comprehensive cancer testing grows, GeneCentric is well-positioned to capture value through partnerships with pharmaceutical companies, academic centers, and clinical laboratories.

Upcoming Catalysts (preview)

• Q4 2026Publication of Clinical Validation Data for Combined DNA/RNA Liquid Biopsy Assay70% success
• H2 2026Strategic Partnership with a Major Pharma for Companion Diagnostic Development50% success
• Q1 2027Receipt of FDA Breakthrough Device Designation for Lead Indication40% success